Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $24.7 million.

  • Cytek Biosciences' Cost of Revenue rose 998.89% to $24.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 98.45%. This contributed to the annual value of $89.3 million for FY2024, which is 688.85% up from last year.
  • Per Cytek Biosciences' latest filing, its Cost of Revenue stood at $24.7 million for Q3 2025, which was up 998.89% from $21.7 million recorded in Q2 2025.
  • Cytek Biosciences' 5-year Cost of Revenue high stood at $25.2 million for Q4 2023, and its period low was $9.8 million during Q1 2021.
  • For the 5-year period, Cytek Biosciences' Cost of Revenue averaged around $18.6 million, with its median value being $20.8 million (2023).
  • In the last 5 years, Cytek Biosciences' Cost of Revenue surged by 5293.43% in 2023 and then plummeted by 540.4% in 2024.
  • Over the past 5 years, Cytek Biosciences' Cost of Revenue (Quarter) stood at $15.3 million in 2021, then rose by 24.28% to $19.0 million in 2022, then soared by 32.82% to $25.2 million in 2023, then decreased by 5.4% to $23.8 million in 2024, then grew by 3.85% to $24.7 million in 2025.
  • Its Cost of Revenue stands at $24.7 million for Q3 2025, versus $21.7 million for Q2 2025 and $21.3 million for Q1 2025.